Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China

  • Zhang P
  • Tan J
  • Lin Y
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Linezolid has been one of the key anti-tuberculosis agents for the treatment of multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB). It used to be very expensive and was not covered by social insurance from local governments. Nevertheless, a growing number of patients in China received linezolid in their anti- MDR/XDR TB regimens over the past decade. Many scholars in China have reported their experience using linezolid to treat patients with MDR/XDR-TB. In view of this, existing evidence of the efficacy and safety of linezolid and problems faced by Chinese patients with MDR/XDR-TB are summarized here.

Cite

CITATION STYLE

APA

Zhang, P., Tan, J., Lin, Y., Zhang, H., Deng, G., & Chen, X. (2022). Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China. Drug Discoveries & Therapeutics, 16(2), 96–98. https://doi.org/10.5582/ddt.2022.01024

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free